pandem
pose
signific
risk
patient
undergo
hematopoiet
stem
cell
transplant
cellular
therapi
american
societi
transplant
cellular
therapi
pharmaci
special
interest
group
steer
committe
aim
provid
pharmaci
practic
manag
recommend
transit
clinic
hematopoiet
stem
cell
transplant
hct
cellular
therapi
pharmaci
servic
util
telemedicin
capabl
inpati
outpati
set
maintain
equival
level
clinic
practic
minim
viral
spread
high
risk
immunocompromis
popul
addit
steer
committe
offer
clinic
manag
recommend
hct
cellular
therapi
patient
base
rapidli
develop
literatur
therapeut
support
care
intervent
increas
collabor
clinic
pharmaci
provid
critic
ensur
safe
administr
hct
patient
attent
drugdrug
interact
ddi
toxic
particularli
qtc
prolong
warrant
close
cardiac
monitor
potenti
cessat
concomit
qtc
prolong
agent
expand
indic
hydroxychloroquin
tocilizumab
alreadi
shown
potenti
stress
usual
suppli
chain
detail
prescrib
algorithm
decis
pathway
specif
patient
popul
stock
may
necessari
pandem
challeng
everi
member
healthcar
team
must
continu
remain
vigil
provid
pharmaci
clinic
servic
one
highrisk
patient
popul
remain
commit
provid
compassion
safe
care
patient
receiv
hct
cellular
therapi
march
world
health
organ
declar
new
coronaviru
global
pandem
ill
highli
contagi
pose
signific
risk
immunocompromis
patient
patient
undergo
hematopoiet
stem
cell
transplant
hct
cellular
therapi
except
current
report
outcom
patient
howev
earli
account
outcom
patient
cancer
infect
indic
time
higher
risk
icu
admiss
mechan
ventil
die
compar
patient
without
cancer
viru
continu
spread
throughout
unit
state
mani
hospit
work
rapidli
conserv
resourc
protect
patient
respons
pandem
avoid
exposur
adher
good
hygien
practic
social
distanc
prevent
strategi
approv
treatment
option
avail
vaccin
patient
hematolog
malign
receiv
hct
cellular
therapi
mani
case
treatment
delay
limit
recommend
pharmacist
practic
work
hct
cellular
therapi
patient
remain
critic
requir
compon
health
care
team
must
ensur
continu
monitor
patient
provid
clinic
recommend
provid
critic
educ
patient
need
american
societi
transplant
cellular
therapi
astct
pharmaci
special
interest
group
sig
steer
committe
provid
posit
statement
pharmaci
practic
manag
clinic
manag
recommend
hct
cellular
therapi
patient
publish
report
manag
cancer
care
pandem
resourc
avail
astct
european
societi
blood
marrow
transplant
ebmt
report
knowledg
specif
address
pharmacist
practic
manag
inpati
outpati
set
leverag
telemedicin
capabl
unpreced
cicrumst
addit
mani
institut
includ
academ
learn
environ
frequent
student
pharmaci
resid
due
concern
mani
chang
implement
consider
alway
given
institut
polici
procedur
practic
routin
review
given
unpreced
time
prioriti
given
protect
vulner
patient
popul
also
ensur
safe
work
environ
protect
health
frontlin
staff
staff
member
must
remain
work
polici
procedur
place
strict
stay
home
sick
polici
clear
guidelin
staff
return
work
safe
take
care
patient
addit
facemask
guidanc
use
person
protect
equip
ppe
also
outlin
within
institut
polici
procedur
despit
initi
prepar
flexibl
frequent
typic
daili
commun
staff
vital
ensur
care
continu
remain
dynam
quickli
evolv
situat
clinic
pharmaci
servic
establish
practic
within
hct
cellular
therapi
team
astct
pharmaci
sig
recommend
continu
pharmacist
monitor
highrisk
complex
patient
access
health
care
team
clinic
decisionmak
role
hct
pharmacist
vital
safeti
optim
care
hct
patient
must
maintain
fact
complianc
depend
model
inpati
round
institut
recommend
limit
exposur
patient
team
member
much
possibl
recogn
import
onsit
represent
inpati
clinic
pharmaci
servic
urgent
emerg
need
rotat
model
work
remot
pharmacist
recommend
limit
number
pharmacist
may
expos
expos
patient
colleagu
attend
inperson
round
deem
necessari
recommend
follow
avoid
enter
patient
room
possibl
conserv
person
protect
equip
ppe
remain
feet
team
member
dress
scrub
routin
launder
institut
provid
scrub
laundri
servic
could
ideal
resourc
avail
modern
emr
support
technolog
allow
pharmacist
abil
complet
profil
review
pharmacokinet
monitor
eg
immunosuppress
renal
hepat
adjust
chemotherapi
entri
verif
evalu
drugdrug
interact
medic
reconcili
remot
addit
recommend
consider
given
standard
time
medic
administr
limit
number
time
nurs
respiratori
therapist
need
enter
patient
room
consider
also
given
plan
mitig
potenti
drug
shortag
identifi
potenti
therapeut
altern
necessari
creat
patient
select
criteria
conserv
suppli
inpati
clinic
pharmaci
servic
hct
cellular
therapi
patient
neg
impact
sacrif
despit
need
limit
facetofac
patient
caregiv
interact
outpati
clinic
critic
acut
manag
longterm
chronic
manag
hct
pharmacist
onsit
may
continu
see
patient
clinic
need
identifi
way
minim
contact
patient
rout
inform
andor
materi
primari
provid
interfac
patient
modern
technolog
provid
within
institut
support
remot
clinic
pharmaci
servic
inpati
outpati
set
critic
success
deliveri
care
effort
limit
patient
contact
consid
outbreak
mani
school
pharmaci
chosen
cancel
inperson
class
favor
onlin
approach
mani
student
clinic
rotat
cancel
chang
virtual
learn
present
uniqu
challeng
casebas
learn
benefici
astct
pharmaci
sig
recommend
student
remain
clinic
rotat
learner
work
remot
review
patient
provid
potenti
clinic
intervent
discuss
primari
preceptor
patient
discuss
recommend
topic
discuss
requir
assign
complet
primari
preceptor
via
platform
skype
student
may
also
assign
academ
research
type
rotat
ensur
exposur
patient
minim
regard
current
resid
understand
pandem
present
uniqu
challeng
howev
believ
best
interest
resid
treat
clinic
staff
resid
exposur
limit
possibl
therefor
complet
clinic
duti
remot
abl
patient
monitor
topic
discuss
preceptor
complet
remot
well
pharmaci
resid
may
also
request
assist
department
need
plan
commun
drug
inform
request
aid
staf
ultim
respons
resid
program
director
ensur
pharmaci
resid
continu
meet
goal
object
outlin
meet
requir
graduat
novel
data
support
potenti
treatment
option
emerg
record
pace
fuel
heavi
debat
regard
studi
design
optim
strategi
tabl
complet
list
ddi
potenti
treatment
visit
http
chloroquin
cq
hydroxychloroquin
hcq
garner
signific
interest
potenti
option
treat
invitro
data
demonstr
possibl
viral
inhibit
increas
ph
intracellular
lysosom
endosom
lead
decreas
viral
membran
fusion
mechan
viral
inhibit
involv
alter
glycosyl
well
block
transport
subsequ
releas
viral
genom
pharmacodynam
cqhcq
readili
bioavail
drug
respect
rapid
peak
concentr
display
multicompart
pharmacokinet
signific
tissu
distribut
long
termin
halfliv
day
convert
activ
metabolit
cytochrom
enzym
cyp
lesser
extent
drug
also
shown
moder
inhibit
cyp
base
metabol
pathway
administr
cyp
inhibitor
may
result
decreas
activ
cqhcq
concentr
coadministr
substrat
may
increas
concentr
coadminist
drug
two
case
report
significantli
elev
cyclosporin
concentr
given
combin
cq
document
ddi
tacrolimu
suggest
interact
cyp
mediat
frequenc
signific
mechan
report
interact
cyclosporin
unknown
routin
pharmacokinet
monitor
recommend
regard
administr
either
agent
recommend
avoid
give
antacid
within
hour
ensur
absorpt
patient
compromis
oral
intak
eg
mucos
hcq
crush
bedsid
must
compound
solut
extern
layer
remov
cellular
therapi
popul
overlap
toxic
concomit
medic
cq
hcq
associ
qtc
prolong
especi
problemat
hct
patient
receiv
multipl
qtc
prolong
agent
azol
antifung
fluoroquinolon
macrolid
azithromycin
antagonist
etc
electrocardiogram
obtain
prior
start
antivir
therapi
cqhcq
earli
report
dual
therapi
hcq
azithromycin
rais
consider
concern
qtc
prolong
warrant
discuss
risk
versu
benefit
vigil
electrolyt
replet
also
recommend
hct
patient
commonli
signific
electrolyt
disturb
increas
risk
cardiac
arrhythmia
rare
notabl
advers
effect
seen
agent
alter
insulin
metabol
lead
hypoglycem
event
patient
concurr
diabet
therapi
appropri
monitor
close
toxic
note
drug
label
includ
elev
liver
function
test
ophthalm
chang
dehydrogenas
deficiencyrel
anemia
ophthalm
toxic
typic
associ
consist
drug
concentr
mgkgday
year
toxic
observ
retrospect
review
patient
receiv
hcq
autoimmun
diseas
given
short
cours
riskbenefit
ratio
initi
direct
therapi
potenti
toxic
less
concern
howev
assess
would
ideal
remdesivir
investig
compound
broadspectrum
antivir
activ
first
develop
ebola
outbreak
remdesivir
nucleotid
prodrug
metabol
activ
nucleosid
triphosph
form
bind
rnadepend
rna
polymeras
act
delay
rna
chain
termin
remdesivir
demonstr
invitro
invivo
activ
anim
first
merscov
potent
invitro
activ
current
dose
studi
mg
iv
day
follow
mg
iv
daili
day
unit
state
remdesivir
avail
clinic
trial
via
compassion
use
howev
march
gilead
inc
temporarili
halt
use
individu
compassion
basi
due
overwhelm
request
still
avail
pregnant
women
children
year
age
sever
outsid
clinic
trial
point
although
remdesivir
describ
substrat
invitro
thought
inhibitor
induc
unlik
caus
signific
drug
interact
sinc
remdesivir
metabol
like
mediat
hydrolas
activ
ribavirin
ribavirin
first
discov
use
treatment
hepat
c
respiratori
syncyti
viru
viral
hemorrhag
fever
nucleosid
inhibitor
termin
rna
synthesi
ribavirin
use
combin
drug
corticosteroid
interferon
util
treatment
merscov
high
dose
gram
gram
everi
hour
associ
excess
toxic
studi
combin
interferon
lopinavirritonavir
ribavirin
minim
druginteract
note
howev
follow
may
increas
risk
myelosuppress
given
combin
azathioprin
linezolid
amphotericin
b
lopinovairritonavir
combin
lopinavir
ritonavir
conjunct
antivir
agent
antivir
regimen
current
approv
treat
lopinavir
ritonavir
proteas
inhibitor
coformul
base
pharmacokinet
profil
ritonavir
increas
plasma
halflif
lopinavir
via
inhibit
cytochrom
metabol
lopinavirritonavir
consid
strong
inhibitor
increas
serum
level
substrat
necessit
dose
adjust
avoid
depend
specif
drug
substrat
lopinavirritonavir
first
identifi
antivir
activ
sarscov
initi
rescu
therapi
ad
patient
treat
ribavirin
steroid
combin
show
reduct
overal
death
rate
intub
rate
advers
event
develop
ard
nosocomi
infect
need
rescu
puls
steroid
sever
respiratori
deterior
unfortun
benefit
carri
report
thu
far
patient
receiv
therapi
tocilizumab
tocilizumab
util
adjunct
therapi
patient
display
sign
cytokin
releas
syndrom
cr
monoclon
antibodi
direct
toward
receptor
undergo
cyp
metabol
elimin
bind
target
patient
oral
inhibitor
ruxolitinib
commonli
use
hct
popul
treatment
steroid
refractori
acut
graft
versu
host
diseas
gvhd
potent
immunosuppress
properti
also
investig
cr
upcom
phase
iii
trial
ruxolitinib
extens
metabol
requir
dose
adjust
strong
inhibitorsinduc
dose
adjust
renal
dysfunct
also
warrant
myelosuppress
infect
common
toxic
use
set
gvhd
treatment
howev
may
profound
use
short
cours
covid
pandem
challeng
everi
member
healthcar
team
short
period
time
major
restructur
staf
model
occur
addit
clinic
manag
patient
consid
rapidli
evolv
clinic
literatur
must
also
remain
top
prioriti
clinic
trial
involv
potenti
treatment
option
quickli
design
must
continu
remain
vigil
provid
pharmaci
clinic
servic
one
highrisk
patient
popul
remain
commit
provid
compassion
safe
care
patient
receiv
hct
cellular
therapi
